董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Rothera | 男 | President, Chief Executive Officer and Director | 56 | 未披露 | 未持股 | 2018-09-30 |
| Bobby Gaspar | 男 | Chief Scientific Officer and Director | 54 | 未披露 | 未持股 | 2018-09-30 |
| Joanne T. Beck | 女 | Director | 57 | 未披露 | 未持股 | 2018-09-30 |
| Jon Ellis | -- | Director | 51 | 未披露 | 未持股 | 2018-09-30 |
| Alex Pasteur | -- | Director | 47 | 未披露 | 未持股 | 2018-09-30 |
| Hong Fang Song | 女 | Director | 53 | 未披露 | 未持股 | 2018-09-30 |
| Elise Wang | 女 | Director | 59 | 未披露 | 未持股 | 2018-09-30 |
| Charles A. Rowland, Jr. | 男 | Director | 60 | 未披露 | 未持股 | 2018-09-30 |
| Marc Dunoyer | 男 | Director | 65 | 未披露 | 未持股 | 2018-09-30 |
| James Arthur Geraghty | 男 | Chairman of the Board of Director | 63 | 未披露 | 未持股 | 2018-09-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Rothera | 男 | President, Chief Executive Officer and Director | 56 | 未披露 | 未持股 | 2018-09-30 |
| Bobby Gaspar | 男 | Chief Scientific Officer and Director | 54 | 未披露 | 未持股 | 2018-09-30 |
| Frank E. Thomas | 男 | Chief Financial Officer and Chief Business Officer | 48 | 未披露 | 未持股 | 2018-09-30 |
董事简历
中英对照 | 中文 | 英文- Mark Rothera
-
Mark Rothera自2017年8月以来一直担任我们的总裁，首席执行官和董事会成员。此前，Rothera先生于2013年4月至2017年8月担任上市生物制药公司PtcTherapeutics，Inc.的首席商务官。在加入PtcTherapeutics，Inc.之前，Rothera先生于2012年4月至2013年1月担任生物制药公司AegerionPharmaceuticals，Inc.的全球总裁。2006年1月至2012年3月，他担任Shire Human Genetic Therapies，Inc.在欧洲、中东和非洲的Vice President和商业运营总经理。加入Shire之前，Rothera从2000年9月到2005年4月担任Chiron Biopharmaceuticals欧洲、中东和非洲地区副总裁。任职Chiron公司之前，Rothera先生曾在Glaxo Wellcome公司的法国和英国业务部门担任各种全球战略和运营市场营销与销售职务。Rothera先生拥有剑桥大学（Cambridge University）自然科学硕士学位，欧洲工商管理学院（European Institute of Business Administration）工商管理硕士学位和英国董事学院（Institute of Directors，United Kingdom）公司方向文凭。
Mark Rothera has served as our President and Chief Executive Officer and as a member of our board of directors since September 2020. From August 2017 to March 2020 Mr. Rothera served as President and Chief Executive Officer and member of the board of Orchard Therapeutics, during which time Orchard completed an initial public offering of American Depositary Shares on the Nasdaq Global Market. From 2013 to August 2017 Mr. Rothera served as Chief Commercial Officer of PTC Therapeutics, becoming a Nasdaq listed biopharmaceutical company with a global commercial footprint during his tenure. From 2012 to 2013 he served as Global President of Aegerion Pharmaceuticals Inc. and from 2006 to 2012 as Vice President and General Manager for the commercial operations of Shire Human Genetic Therapies, Inc. in Europe, the Middle East and Africa. Mr. Rothera served as Area VP Europe, Middle East and Africa for Chiron BioPharmaceuticals from 2000 to 2005 and previously held various global strategic and operational marketing and sales roles with French and UK operations of Glaxo Wellcome. Mr. Rothera currently sits on the board of GenPharm. Mr. Rothera received an M.A. in Natural Sciences from Cambridge University, an M.B.A. from the European Institute for Business Administration INSEAD and a Diploma in Company Direction from Institute of Directors, United Kingdom. - Mark Rothera自2017年8月以来一直担任我们的总裁，首席执行官和董事会成员。此前，Rothera先生于2013年4月至2017年8月担任上市生物制药公司PtcTherapeutics，Inc.的首席商务官。在加入PtcTherapeutics，Inc.之前，Rothera先生于2012年4月至2013年1月担任生物制药公司AegerionPharmaceuticals，Inc.的全球总裁。2006年1月至2012年3月，他担任Shire Human Genetic Therapies，Inc.在欧洲、中东和非洲的Vice President和商业运营总经理。加入Shire之前，Rothera从2000年9月到2005年4月担任Chiron Biopharmaceuticals欧洲、中东和非洲地区副总裁。任职Chiron公司之前，Rothera先生曾在Glaxo Wellcome公司的法国和英国业务部门担任各种全球战略和运营市场营销与销售职务。Rothera先生拥有剑桥大学（Cambridge University）自然科学硕士学位，欧洲工商管理学院（European Institute of Business Administration）工商管理硕士学位和英国董事学院（Institute of Directors，United Kingdom）公司方向文凭。
- Mark Rothera has served as our President and Chief Executive Officer and as a member of our board of directors since September 2020. From August 2017 to March 2020 Mr. Rothera served as President and Chief Executive Officer and member of the board of Orchard Therapeutics, during which time Orchard completed an initial public offering of American Depositary Shares on the Nasdaq Global Market. From 2013 to August 2017 Mr. Rothera served as Chief Commercial Officer of PTC Therapeutics, becoming a Nasdaq listed biopharmaceutical company with a global commercial footprint during his tenure. From 2012 to 2013 he served as Global President of Aegerion Pharmaceuticals Inc. and from 2006 to 2012 as Vice President and General Manager for the commercial operations of Shire Human Genetic Therapies, Inc. in Europe, the Middle East and Africa. Mr. Rothera served as Area VP Europe, Middle East and Africa for Chiron BioPharmaceuticals from 2000 to 2005 and previously held various global strategic and operational marketing and sales roles with French and UK operations of Glaxo Wellcome. Mr. Rothera currently sits on the board of GenPharm. Mr. Rothera received an M.A. in Natural Sciences from Cambridge University, an M.B.A. from the European Institute for Business Administration INSEAD and a Diploma in Company Direction from Institute of Directors, United Kingdom.
- Bobby Gaspar
-
Bobby Gaspar自2016年2月起担任我们的首席科学官和董事会成员。Gaspar博士加入UCL和Gosh，对基因治疗感兴趣。2007年10月以来，他一直担任UCL Institute of Child Health的儿科和免疫学教授，以及Gosh的儿科免疫学荣誉顾问。Gaspar博士拥有伦敦国王学院（Kings College London）的工商管理硕士学位和UCL的博士学位。
Bobby Gaspar has served as our Chief Scientific Officer and as a member of our board of directors since February 2016. Dr. Gaspar joined UCL and GOSH with an interest in gene therapy. Since October 2007 he has been professor of pediatrics and immunology at the UCL Institute of Child Health and Honorary Consultant in pediatric immunology at GOSH. Dr. Gaspar holds an M.B. B.S. from Kings College London and a Ph.D. from UCL. - Bobby Gaspar自2016年2月起担任我们的首席科学官和董事会成员。Gaspar博士加入UCL和Gosh，对基因治疗感兴趣。2007年10月以来，他一直担任UCL Institute of Child Health的儿科和免疫学教授，以及Gosh的儿科免疫学荣誉顾问。Gaspar博士拥有伦敦国王学院（Kings College London）的工商管理硕士学位和UCL的博士学位。
- Bobby Gaspar has served as our Chief Scientific Officer and as a member of our board of directors since February 2016. Dr. Gaspar joined UCL and GOSH with an interest in gene therapy. Since October 2007 he has been professor of pediatrics and immunology at the UCL Institute of Child Health and Honorary Consultant in pediatric immunology at GOSH. Dr. Gaspar holds an M.B. B.S. from Kings College London and a Ph.D. from UCL.
- Joanne T. Beck
-
JoanneT.Beck自2018年7月以来一直是我们的董事会成员。自2016年4月以来，贝克博士一直担任Celgene的执行Vice President，药物开发和运营。在加入Celgene之前，贝克博士于2012年1月至2016年4月担任Shire制药开发高级副总裁，。Beck从2004年5月到2012年1月担任Abbott制药和血管运营领导职位，最近担任全球卓越业务和战略计划管理主管。职业生涯早期，她曾担任Amgen公司和Genentech公司的技术领导职务。Beck博士拥有Lewis and Clark College化学学士学位和Oregon Health and Science University生物化学和分子生物学博士学位。
Joanne T. Beck has been a member of our board of directors since July 2018. Since April 2016 Dr. Beck has served as the Executive Vice President, Pharmaceutical Development & Operations at Celgene. Prior to joining Celgene, Dr. Beck was the Senior Vice President, Pharmaceutical Development at Shire from January 2012 to April 2016. From May 2004 to January 2012 Dr. Beck held leadership roles in both Pharmaceutical and Vascular Operations at Abbott, most recently as Head of Global Business Excellence and Strategic Program Management. Earlier in her career she had technical leadership roles at Amgen and Genentech. Dr. Beck holds a B.A. in Chemistry from Lewis and Clark College and a Ph.D. in Biochemistry and Molecular Biology from Oregon Health and Science University. - JoanneT.Beck自2018年7月以来一直是我们的董事会成员。自2016年4月以来，贝克博士一直担任Celgene的执行Vice President，药物开发和运营。在加入Celgene之前，贝克博士于2012年1月至2016年4月担任Shire制药开发高级副总裁，。Beck从2004年5月到2012年1月担任Abbott制药和血管运营领导职位，最近担任全球卓越业务和战略计划管理主管。职业生涯早期，她曾担任Amgen公司和Genentech公司的技术领导职务。Beck博士拥有Lewis and Clark College化学学士学位和Oregon Health and Science University生物化学和分子生物学博士学位。
- Joanne T. Beck has been a member of our board of directors since July 2018. Since April 2016 Dr. Beck has served as the Executive Vice President, Pharmaceutical Development & Operations at Celgene. Prior to joining Celgene, Dr. Beck was the Senior Vice President, Pharmaceutical Development at Shire from January 2012 to April 2016. From May 2004 to January 2012 Dr. Beck held leadership roles in both Pharmaceutical and Vascular Operations at Abbott, most recently as Head of Global Business Excellence and Strategic Program Management. Earlier in her career she had technical leadership roles at Amgen and Genentech. Dr. Beck holds a B.A. in Chemistry from Lewis and Clark College and a Ph.D. in Biochemistry and Molecular Biology from Oregon Health and Science University.
- Jon Ellis
-
Jon Ellis自2018年7月以来一直是我们的董事会成员。自2016年1月以来，Ellis博士一直担任GlaxoSmithKline plc（一家公开上市的制药公司）的Vice President兼科技许可制药研发主管。在GSK，Ellis博士还担任过Vice President&；Platforms BD&；Academic负责人、Vice President&；Platforms BD负责人、Vice President&；Biopharm BD负责人以及抗体工程和生物危害许可负责人。在2001年加入GSK之前，Ellis博士从1995年11月到2001年1月在GlaxoWellcome plc（一家前上市制药公司）担任集团领导。1995年加入GlaxoWellcome之前，Ellis从1993年11月到1995年11月担任Wellcome Foundation Ltd（一家前上市制药公司）高级分子生物学家。在1993年加入Wellcome Foundation之前，从1992年10月到1993年11月，Ellis博士是Quantum Biosystems Ltd的职员科学家。Ellis博士拥有剑桥大学抹大拉学院（Magdalene College）的学士学位和硕士学位，剑桥大学（University of Cambridge）的博士学位，以及亨利管理学院（Henley Management College）的工商管理硕士学位。
Jon Ellis has been a member of our board of directors since July 2018. Since January 2016 Dr. Ellis has served as the Vice President and Head, Science & Technology Licensing Pharmaceuticals R&D at GlaxoSmithKline plc, a publicly traded pharmaceutical company. At GSK, Dr. Ellis has also held the roles of Vice President & Head of Platforms BD & Academic, Vice President & Head of Platforms BD, Vice President & Head of Biopharmaceuticals BD, as well as the Head of Antibody Engineering and Biopharm Licensing. Prior to joining GSK in 2001 Dr. Ellis worked as a group leader at GlaxoWellcome plc, a former publicly traded pharmaceutical company, from November 1995 to January 2001. Prior to joining GlaxoWellcome in 1995 Dr. Ellis was a Senior Molecular Biologist at Wellcome Foundation Ltd, a former publicly traded pharmaceutical company, from November 1993 to November 1995. Prior to joining Wellcome Foundation in 1993 Dr. Ellis was a staff scientist at Quantum Biosystems Ltd from October 1992 to November 1993. Dr. Ellis holds a B.A. and M.A. from Magdalene College, University of Cambridge, a Ph.D. from the University of Cambridge, and an M.B.A. from Henley Management College. - Jon Ellis自2018年7月以来一直是我们的董事会成员。自2016年1月以来，Ellis博士一直担任GlaxoSmithKline plc（一家公开上市的制药公司）的Vice President兼科技许可制药研发主管。在GSK，Ellis博士还担任过Vice President&；Platforms BD&；Academic负责人、Vice President&；Platforms BD负责人、Vice President&；Biopharm BD负责人以及抗体工程和生物危害许可负责人。在2001年加入GSK之前，Ellis博士从1995年11月到2001年1月在GlaxoWellcome plc（一家前上市制药公司）担任集团领导。1995年加入GlaxoWellcome之前，Ellis从1993年11月到1995年11月担任Wellcome Foundation Ltd（一家前上市制药公司）高级分子生物学家。在1993年加入Wellcome Foundation之前，从1992年10月到1993年11月，Ellis博士是Quantum Biosystems Ltd的职员科学家。Ellis博士拥有剑桥大学抹大拉学院（Magdalene College）的学士学位和硕士学位，剑桥大学（University of Cambridge）的博士学位，以及亨利管理学院（Henley Management College）的工商管理硕士学位。
- Jon Ellis has been a member of our board of directors since July 2018. Since January 2016 Dr. Ellis has served as the Vice President and Head, Science & Technology Licensing Pharmaceuticals R&D at GlaxoSmithKline plc, a publicly traded pharmaceutical company. At GSK, Dr. Ellis has also held the roles of Vice President & Head of Platforms BD & Academic, Vice President & Head of Platforms BD, Vice President & Head of Biopharmaceuticals BD, as well as the Head of Antibody Engineering and Biopharm Licensing. Prior to joining GSK in 2001 Dr. Ellis worked as a group leader at GlaxoWellcome plc, a former publicly traded pharmaceutical company, from November 1995 to January 2001. Prior to joining GlaxoWellcome in 1995 Dr. Ellis was a Senior Molecular Biologist at Wellcome Foundation Ltd, a former publicly traded pharmaceutical company, from November 1993 to November 1995. Prior to joining Wellcome Foundation in 1993 Dr. Ellis was a staff scientist at Quantum Biosystems Ltd from October 1992 to November 1993. Dr. Ellis holds a B.A. and M.A. from Magdalene College, University of Cambridge, a Ph.D. from the University of Cambridge, and an M.B.A. from Henley Management College.
- Alex Pasteur
-
Alex Pasteur自2015年11月以来一直是我们的董事会成员。Pasteur博士是F-Prime Capital Partners驻伦敦的合伙人，自2015年1月起担任合伙人。在F-Prime Capital Partners，从2012年10月到2014年12月，Pasteur博士还担任负责人。此外，巴斯德博士于2016年9月至2017年9月担任我们的首席执行官。此前，Pasteur博士在美国和欧洲的MVM Life Science Partners LLP任职。Pasteur博士拥有剑桥大学（Cambridge University）自然科学硕士学位和化学博士学位。
Alex Pasteur has been a member of our board of directors since November 2015. Dr. Pasteur is a London-based partner at F-Prime Capital Partners and has been a partner since January 2015. At F-Prime Capital Partners, Dr. Pasteur also held the role of Principal from October 2012 to December 2014. Additionally, Dr. Pasteur served as our Chief Executive Officer from September 2016 to September 2017. Previously, Dr. Pasteur worked at MVM Life Science Partners LLP in the USA and Europe. Dr. Pasteur holds an M.A. in Natural Sciences and a Ph.D. in Chemistry from Cambridge University. - Alex Pasteur自2015年11月以来一直是我们的董事会成员。Pasteur博士是F-Prime Capital Partners驻伦敦的合伙人，自2015年1月起担任合伙人。在F-Prime Capital Partners，从2012年10月到2014年12月，Pasteur博士还担任负责人。此外，巴斯德博士于2016年9月至2017年9月担任我们的首席执行官。此前，Pasteur博士在美国和欧洲的MVM Life Science Partners LLP任职。Pasteur博士拥有剑桥大学（Cambridge University）自然科学硕士学位和化学博士学位。
- Alex Pasteur has been a member of our board of directors since November 2015. Dr. Pasteur is a London-based partner at F-Prime Capital Partners and has been a partner since January 2015. At F-Prime Capital Partners, Dr. Pasteur also held the role of Principal from October 2012 to December 2014. Additionally, Dr. Pasteur served as our Chief Executive Officer from September 2016 to September 2017. Previously, Dr. Pasteur worked at MVM Life Science Partners LLP in the USA and Europe. Dr. Pasteur holds an M.A. in Natural Sciences and a Ph.D. in Chemistry from Cambridge University.
- Hong Fang Song
-
Hong Fang Song自2017年9月以来一直担任我们的董事会成员。宋女士是ORI Capital的创始人，自2015年7月起担任ORI Capital的高级合伙人。此前，宋女士于2010年1月至2015年6月担任跨国投资银行和金融服务公司高盛（Goldman Sachs）中国梦百合业务部董事总经理。宋女士拥有中国复旦大学经济学学士学位和美国克莱蒙特研究生院经济学硕士学位。
Hong Fang Song,has served as a member of Cg Oncology, Inc. board of directors since November 2015. Ms. Song is the Founder and has been a Senior Partner of ORI Capital Limited, a venture capital firm, since July 2015. Prior to ORI Capital, Ms. Song served as the Head of Healthcare Investment Banking for Greater China for Goldman Sachs. Prior to Goldman Sachs, Ms. Song was a Managing Director of Cowen, a member of the advisory board of AXA Investment Managers, a global investment management firm, and an executive board advisor to AXA Asia Pacific Holdings Limited. Ms. Hong holds a B.A. in Economics from Fudan University and an M.A. in Economics from Claremont Graduate School. - Hong Fang Song自2017年9月以来一直担任我们的董事会成员。宋女士是ORI Capital的创始人，自2015年7月起担任ORI Capital的高级合伙人。此前，宋女士于2010年1月至2015年6月担任跨国投资银行和金融服务公司高盛（Goldman Sachs）中国梦百合业务部董事总经理。宋女士拥有中国复旦大学经济学学士学位和美国克莱蒙特研究生院经济学硕士学位。
- Hong Fang Song,has served as a member of Cg Oncology, Inc. board of directors since November 2015. Ms. Song is the Founder and has been a Senior Partner of ORI Capital Limited, a venture capital firm, since July 2015. Prior to ORI Capital, Ms. Song served as the Head of Healthcare Investment Banking for Greater China for Goldman Sachs. Prior to Goldman Sachs, Ms. Song was a Managing Director of Cowen, a member of the advisory board of AXA Investment Managers, a global investment management firm, and an executive board advisor to AXA Asia Pacific Holdings Limited. Ms. Hong holds a B.A. in Economics from Fudan University and an M.A. in Economics from Claremont Graduate School.
- Elise Wang
-
Elise Wang自2018年8月以来一直是我们的董事会成员。王女士目前是Deerfield Management Company，L.P.公共结构融资集团的负责人，自2010年以来一直在Deerfield任职。在加入Deerfield之前，Wang女士从2001年到2007年担任花旗集团（Citigroup）梦百合高级研究分析师和董事总经理，主要负责生物技术行业。从1996年到2001年，她曾担任PaineWebber公司的高级研究分析师兼董事总经理，在那里她曾负责生物技术。王女士于1987年在梦百合开始她的职业生涯，担任PaineWebber Inc.的风险投资家和银行家，并担任PaineWebber Development Corporation的高级管理人员，该公司管理投资于生物技术和高科技公司的实体。王女士拥有哈佛大学生物力学专业的工程科学学士学位和哈佛商学院的工商管理硕士学位。
Elise Wang has been a member of our board of directors since August 2018. Ms. Wang is currently a Principal on the Public Structured Finance group at Deerfield Management Company, L.P., and has been with Deerfield since 2010. Prior to joining Deerfield, from 2001 to 2007 Ms. Wang was a Senior Research Analyst and Managing Director in healthcare primarily covering the biotechnology industry at Citigroup. From 1996 to 2001 Ms. Wang was a Senior Research Analyst and Managing Director at PaineWebber Inc., where she covered biotechnology. Ms. Wang began her career in healthcare in 1987 as a venture capitalist and banker at PaineWebber Inc. and was an officer of PaineWebber Development Corporation, which managed entities invested in biotechnology and high technology companies. Ms. Wang holds an A.B. in Engineering Sciences with a specialty in Biomechanics from Harvard University and an M.B.A. from Harvard Business School. - Elise Wang自2018年8月以来一直是我们的董事会成员。王女士目前是Deerfield Management Company，L.P.公共结构融资集团的负责人，自2010年以来一直在Deerfield任职。在加入Deerfield之前，Wang女士从2001年到2007年担任花旗集团（Citigroup）梦百合高级研究分析师和董事总经理，主要负责生物技术行业。从1996年到2001年，她曾担任PaineWebber公司的高级研究分析师兼董事总经理，在那里她曾负责生物技术。王女士于1987年在梦百合开始她的职业生涯，担任PaineWebber Inc.的风险投资家和银行家，并担任PaineWebber Development Corporation的高级管理人员，该公司管理投资于生物技术和高科技公司的实体。王女士拥有哈佛大学生物力学专业的工程科学学士学位和哈佛商学院的工商管理硕士学位。
- Elise Wang has been a member of our board of directors since August 2018. Ms. Wang is currently a Principal on the Public Structured Finance group at Deerfield Management Company, L.P., and has been with Deerfield since 2010. Prior to joining Deerfield, from 2001 to 2007 Ms. Wang was a Senior Research Analyst and Managing Director in healthcare primarily covering the biotechnology industry at Citigroup. From 1996 to 2001 Ms. Wang was a Senior Research Analyst and Managing Director at PaineWebber Inc., where she covered biotechnology. Ms. Wang began her career in healthcare in 1987 as a venture capitalist and banker at PaineWebber Inc. and was an officer of PaineWebber Development Corporation, which managed entities invested in biotechnology and high technology companies. Ms. Wang holds an A.B. in Engineering Sciences with a specialty in Biomechanics from Harvard University and an M.B.A. from Harvard Business School.
- Charles A. Rowland, Jr.
-
Charles A. Rowland, Jr.（小），2014年9月起成为公司董事会成员。目前他担任战略顾问。2008年10月起到2014年1月公司被Shire plc收购，他担任国际制药公司ViroPharma Incorporated的副总裁兼首席财务官。加入ViroPharma前，2006年12月至2008年9月，他曾是Endo Pharmaceuticals Inc.的执行副总裁、首席财务官和临时联合首席执行官，该公司是一家疼痛管理专业制药公司。2004年至2006年，他担任国际制药公司Biovail Corporation的高级副总裁兼首席财务官。之前，他也曾在Breakaway Technologies公司、Pharmacia Corporation、Novartis AG 和Bristol-Myers Squibb Co。任职。目前他任职于BIND Therapeutics公司和Aurina Pharmaceuticals公司的董事会。2013年至2014年8月公司被默克（Merck & Co., Inc.）收购期间，他任职于Idenix Pharmaceuticals公司的董事会。他同时也是费城Financial Executives International的董事会成员。他取得了圣约瑟夫大学（St. Joseph's University）会计学士和罗格斯大学（Rutgers University）工商管理硕士学位。
Charles A. Rowland, Jr. has served on our board of directors since June 23 2017. Mr. Rowland previously served on the supervisory board of Nabriva Austria from January 2015 until the Redomiciliation. Mr. Rowland served as chief executive officer of Aurinia Pharmaceuticals Inc. from April 2016 to January 2017. Mr. Rowland previously served as vice president and chief financial officer of ViroPharma Incorporated from 2008 until it was acquired by Shire plc in 2014. Prior to joining ViroPharma, Mr. Rowland served as executive vice president and chief financial officer, as well as interim co-chief executive officer, for Endo Pharmaceuticals Inc. from 2006 to 2008 and chief financial officer at Biovail Corporation from 2004 to 2006. He previously held finance and operational positions of increasing responsibility at Breakaway Technologies, Inc., Pharmacia, Novartis International AG and Bristol-Myers Squibb Company. Mr. Rowland currently serves as a member of the board of directors for Blueprint Medicines Corporation, a public biopharmaceutical company, Viking Therapeutics, a public, clinical-stage biopharmaceutical company, and Orchard Therapeutics, a public, clinical-stage biopharmaceutical company. In addition, Mr. Rowland serves as a member of the board of directors for Generation Bio, a privately held biopharmaceutical company. Previously, he served on the board of directors at Idenix Pharmaceuticals, Inc., Vitae Pharmaceuticals, Inc., Bind Therapeutics Inc. and Aurinia Pharmaceuticals Inc. Mr. Rowland received his B.S. from Saint Joseph's University and M.B.A. from Rutgers University. - Charles A. Rowland, Jr.（小），2014年9月起成为公司董事会成员。目前他担任战略顾问。2008年10月起到2014年1月公司被Shire plc收购，他担任国际制药公司ViroPharma Incorporated的副总裁兼首席财务官。加入ViroPharma前，2006年12月至2008年9月，他曾是Endo Pharmaceuticals Inc.的执行副总裁、首席财务官和临时联合首席执行官，该公司是一家疼痛管理专业制药公司。2004年至2006年，他担任国际制药公司Biovail Corporation的高级副总裁兼首席财务官。之前，他也曾在Breakaway Technologies公司、Pharmacia Corporation、Novartis AG 和Bristol-Myers Squibb Co。任职。目前他任职于BIND Therapeutics公司和Aurina Pharmaceuticals公司的董事会。2013年至2014年8月公司被默克（Merck & Co., Inc.）收购期间，他任职于Idenix Pharmaceuticals公司的董事会。他同时也是费城Financial Executives International的董事会成员。他取得了圣约瑟夫大学（St. Joseph's University）会计学士和罗格斯大学（Rutgers University）工商管理硕士学位。
- Charles A. Rowland, Jr. has served on our board of directors since June 23 2017. Mr. Rowland previously served on the supervisory board of Nabriva Austria from January 2015 until the Redomiciliation. Mr. Rowland served as chief executive officer of Aurinia Pharmaceuticals Inc. from April 2016 to January 2017. Mr. Rowland previously served as vice president and chief financial officer of ViroPharma Incorporated from 2008 until it was acquired by Shire plc in 2014. Prior to joining ViroPharma, Mr. Rowland served as executive vice president and chief financial officer, as well as interim co-chief executive officer, for Endo Pharmaceuticals Inc. from 2006 to 2008 and chief financial officer at Biovail Corporation from 2004 to 2006. He previously held finance and operational positions of increasing responsibility at Breakaway Technologies, Inc., Pharmacia, Novartis International AG and Bristol-Myers Squibb Company. Mr. Rowland currently serves as a member of the board of directors for Blueprint Medicines Corporation, a public biopharmaceutical company, Viking Therapeutics, a public, clinical-stage biopharmaceutical company, and Orchard Therapeutics, a public, clinical-stage biopharmaceutical company. In addition, Mr. Rowland serves as a member of the board of directors for Generation Bio, a privately held biopharmaceutical company. Previously, he served on the board of directors at Idenix Pharmaceuticals, Inc., Vitae Pharmaceuticals, Inc., Bind Therapeutics Inc. and Aurinia Pharmaceuticals Inc. Mr. Rowland received his B.S. from Saint Joseph's University and M.B.A. from Rutgers University.
- Marc Dunoyer
-
Marc Dunoyer，Marc于2010年1月被任命为葛兰素史克日本地区的主席，于2010年2月开始领导葛兰素史克罕见疾病业务的研发与商业化。他于1999年加入集团，在这之前，从2000年1月到2008年5月担任日本制药部（Pharmaceuticals Japan）的总裁。他从2008年5月到2010年7月担任亚太地区与日本制药部（Pharmaceuticals Asia Pacific/ Japan）的总裁。
Marc Dunoyer's pharmaceutical career includes periods with Roussel Uclaf, Hoechst Marion Roussel and GSK, which has given him extensive industry experience in: finance and accounting; corporate strategy and planning; research and development; sales and marketing; business reorganisation; and business development. Marc is a qualified accountant and joined AstraZeneca in 2013 serving as Executive Vice-President, Global Product and Portfolio Strategy GPPS from June-October 2013. Previously, he served as Global Head of Rare Diseases at GSK and concurrently Chairman, GSK Japan. He holds an MBA from HEC Paris and a Bachelor of Law degree from Paris University. Marc is a Director of Orchard Therapeutics Plc. - Marc Dunoyer，Marc于2010年1月被任命为葛兰素史克日本地区的主席，于2010年2月开始领导葛兰素史克罕见疾病业务的研发与商业化。他于1999年加入集团，在这之前，从2000年1月到2008年5月担任日本制药部（Pharmaceuticals Japan）的总裁。他从2008年5月到2010年7月担任亚太地区与日本制药部（Pharmaceuticals Asia Pacific/ Japan）的总裁。
- Marc Dunoyer's pharmaceutical career includes periods with Roussel Uclaf, Hoechst Marion Roussel and GSK, which has given him extensive industry experience in: finance and accounting; corporate strategy and planning; research and development; sales and marketing; business reorganisation; and business development. Marc is a qualified accountant and joined AstraZeneca in 2013 serving as Executive Vice-President, Global Product and Portfolio Strategy GPPS from June-October 2013. Previously, he served as Global Head of Rare Diseases at GSK and concurrently Chairman, GSK Japan. He holds an MBA from HEC Paris and a Bachelor of Law degree from Paris University. Marc is a Director of Orchard Therapeutics Plc.
- James Arthur Geraghty
-
James Arthur Geraghty先生，于2018年7月18日获委任为北海康成制药有限公司独立非执行董事。Geraghty先生自2017年5月起担任公司的全资附属公司北海康成医药科技的独立非执行董事。Geraghty先生负责监督董事会并为董事会提供独立判断。Geraghty先生在业务发展、战略及营运方面拥有约30年管理经验。于2013年5月至2016年12月，Geraghty先生为Third Rock Ventures的驻场企业家，负责公司组建及治理。在此之前，Geraghty先生于2011年4月至2012年12月期间担任Sanofi S.A.的高级副总裁，负责战略及业务发展。Geraghty先生于1992年至2011年任职于美国健赞公司，其在此担任的最后职位是负责国际开发的高级副总裁。于1993年至2007年，Geraghty先生担任Genzyme Transgenics Corporation的董事会主席及首席执行官。此前，Geraghty先生在贝恩资本开启职业生涯，负责医疗健康策略咨询。Geraghty先生自2018年5月及2017年11月起分别担任Orchard Therapeutics（纳斯达克：ORTX）及Pieris Pharmaceuticals（纳斯达克：PIRS）的董事会主席。Geraghty先生亦自2016年10月、2014年1月及2013年7月起分别担任Fulcrum Therapeutics（纳斯达克：PIRS）、Voyager Therapeutics（纳斯达克：VYGR）及Idera Pharmaceuticals（纳斯达克：IDRA）的独立非雇员董事。Geraghty先生于1980年5月在乔治敦大学获得心理学学士学位及在耶鲁大学法学院获得法学博士学位。于2018年07月18日获委任为北海康成制药有限公司提名及企业管治委员会委员。于2022年02月16日获委任为北海康成制药有限公司审核委员会委员。
James Arthur Geraghty has served on Idera Pharmaceuticals, Inc. Board of Directors since 2013 and as chair of Idera Pharmaceuticals, Inc. Board of Directors from that time until 2021. Mr. Geraghty is an industry leader with over 35 years of strategic and leadership experience, including more than 25 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. From 2013 to 2016, Mr. Geraghty was an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture fund. From 2011 to 2012, he served as a Senior Vice President of Sanofi S.A., a global healthcare company. Prior to that, he served in various senior management roles at Genzyme Corporation, or Genzyme, a biotechnology company, from 1992 to 2011, including as Senior Vice President of International Development and President of Genzyme Europe. Mr. Geraghty currently serves as chairman of the board of Orchard Therapeutics plc and Pieris Pharmaceuticals, Inc. and as a member of the board of Voyager Therapeutics, Inc., and Fulcrum Therapeutics, Inc. He also previously served as a director of bluebird bio, Inc. and GTC Biotherapeutics, Inc. - James Arthur Geraghty先生，于2018年7月18日获委任为北海康成制药有限公司独立非执行董事。Geraghty先生自2017年5月起担任公司的全资附属公司北海康成医药科技的独立非执行董事。Geraghty先生负责监督董事会并为董事会提供独立判断。Geraghty先生在业务发展、战略及营运方面拥有约30年管理经验。于2013年5月至2016年12月，Geraghty先生为Third Rock Ventures的驻场企业家，负责公司组建及治理。在此之前，Geraghty先生于2011年4月至2012年12月期间担任Sanofi S.A.的高级副总裁，负责战略及业务发展。Geraghty先生于1992年至2011年任职于美国健赞公司，其在此担任的最后职位是负责国际开发的高级副总裁。于1993年至2007年，Geraghty先生担任Genzyme Transgenics Corporation的董事会主席及首席执行官。此前，Geraghty先生在贝恩资本开启职业生涯，负责医疗健康策略咨询。Geraghty先生自2018年5月及2017年11月起分别担任Orchard Therapeutics（纳斯达克：ORTX）及Pieris Pharmaceuticals（纳斯达克：PIRS）的董事会主席。Geraghty先生亦自2016年10月、2014年1月及2013年7月起分别担任Fulcrum Therapeutics（纳斯达克：PIRS）、Voyager Therapeutics（纳斯达克：VYGR）及Idera Pharmaceuticals（纳斯达克：IDRA）的独立非雇员董事。Geraghty先生于1980年5月在乔治敦大学获得心理学学士学位及在耶鲁大学法学院获得法学博士学位。于2018年07月18日获委任为北海康成制药有限公司提名及企业管治委员会委员。于2022年02月16日获委任为北海康成制药有限公司审核委员会委员。
- James Arthur Geraghty has served on Idera Pharmaceuticals, Inc. Board of Directors since 2013 and as chair of Idera Pharmaceuticals, Inc. Board of Directors from that time until 2021. Mr. Geraghty is an industry leader with over 35 years of strategic and leadership experience, including more than 25 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. From 2013 to 2016, Mr. Geraghty was an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture fund. From 2011 to 2012, he served as a Senior Vice President of Sanofi S.A., a global healthcare company. Prior to that, he served in various senior management roles at Genzyme Corporation, or Genzyme, a biotechnology company, from 1992 to 2011, including as Senior Vice President of International Development and President of Genzyme Europe. Mr. Geraghty currently serves as chairman of the board of Orchard Therapeutics plc and Pieris Pharmaceuticals, Inc. and as a member of the board of Voyager Therapeutics, Inc., and Fulcrum Therapeutics, Inc. He also previously served as a director of bluebird bio, Inc. and GTC Biotherapeutics, Inc.
高管简历
中英对照 | 中文 | 英文- Mark Rothera
Mark Rothera自2017年8月以来一直担任我们的总裁，首席执行官和董事会成员。此前，Rothera先生于2013年4月至2017年8月担任上市生物制药公司PtcTherapeutics，Inc.的首席商务官。在加入PtcTherapeutics，Inc.之前，Rothera先生于2012年4月至2013年1月担任生物制药公司AegerionPharmaceuticals，Inc.的全球总裁。2006年1月至2012年3月，他担任Shire Human Genetic Therapies，Inc.在欧洲、中东和非洲的Vice President和商业运营总经理。加入Shire之前，Rothera从2000年9月到2005年4月担任Chiron Biopharmaceuticals欧洲、中东和非洲地区副总裁。任职Chiron公司之前，Rothera先生曾在Glaxo Wellcome公司的法国和英国业务部门担任各种全球战略和运营市场营销与销售职务。Rothera先生拥有剑桥大学（Cambridge University）自然科学硕士学位，欧洲工商管理学院（European Institute of Business Administration）工商管理硕士学位和英国董事学院（Institute of Directors，United Kingdom）公司方向文凭。
Mark Rothera has served as our President and Chief Executive Officer and as a member of our board of directors since September 2020. From August 2017 to March 2020 Mr. Rothera served as President and Chief Executive Officer and member of the board of Orchard Therapeutics, during which time Orchard completed an initial public offering of American Depositary Shares on the Nasdaq Global Market. From 2013 to August 2017 Mr. Rothera served as Chief Commercial Officer of PTC Therapeutics, becoming a Nasdaq listed biopharmaceutical company with a global commercial footprint during his tenure. From 2012 to 2013 he served as Global President of Aegerion Pharmaceuticals Inc. and from 2006 to 2012 as Vice President and General Manager for the commercial operations of Shire Human Genetic Therapies, Inc. in Europe, the Middle East and Africa. Mr. Rothera served as Area VP Europe, Middle East and Africa for Chiron BioPharmaceuticals from 2000 to 2005 and previously held various global strategic and operational marketing and sales roles with French and UK operations of Glaxo Wellcome. Mr. Rothera currently sits on the board of GenPharm. Mr. Rothera received an M.A. in Natural Sciences from Cambridge University, an M.B.A. from the European Institute for Business Administration INSEAD and a Diploma in Company Direction from Institute of Directors, United Kingdom.- Mark Rothera自2017年8月以来一直担任我们的总裁，首席执行官和董事会成员。此前，Rothera先生于2013年4月至2017年8月担任上市生物制药公司PtcTherapeutics，Inc.的首席商务官。在加入PtcTherapeutics，Inc.之前，Rothera先生于2012年4月至2013年1月担任生物制药公司AegerionPharmaceuticals，Inc.的全球总裁。2006年1月至2012年3月，他担任Shire Human Genetic Therapies，Inc.在欧洲、中东和非洲的Vice President和商业运营总经理。加入Shire之前，Rothera从2000年9月到2005年4月担任Chiron Biopharmaceuticals欧洲、中东和非洲地区副总裁。任职Chiron公司之前，Rothera先生曾在Glaxo Wellcome公司的法国和英国业务部门担任各种全球战略和运营市场营销与销售职务。Rothera先生拥有剑桥大学（Cambridge University）自然科学硕士学位，欧洲工商管理学院（European Institute of Business Administration）工商管理硕士学位和英国董事学院（Institute of Directors，United Kingdom）公司方向文凭。
- Mark Rothera has served as our President and Chief Executive Officer and as a member of our board of directors since September 2020. From August 2017 to March 2020 Mr. Rothera served as President and Chief Executive Officer and member of the board of Orchard Therapeutics, during which time Orchard completed an initial public offering of American Depositary Shares on the Nasdaq Global Market. From 2013 to August 2017 Mr. Rothera served as Chief Commercial Officer of PTC Therapeutics, becoming a Nasdaq listed biopharmaceutical company with a global commercial footprint during his tenure. From 2012 to 2013 he served as Global President of Aegerion Pharmaceuticals Inc. and from 2006 to 2012 as Vice President and General Manager for the commercial operations of Shire Human Genetic Therapies, Inc. in Europe, the Middle East and Africa. Mr. Rothera served as Area VP Europe, Middle East and Africa for Chiron BioPharmaceuticals from 2000 to 2005 and previously held various global strategic and operational marketing and sales roles with French and UK operations of Glaxo Wellcome. Mr. Rothera currently sits on the board of GenPharm. Mr. Rothera received an M.A. in Natural Sciences from Cambridge University, an M.B.A. from the European Institute for Business Administration INSEAD and a Diploma in Company Direction from Institute of Directors, United Kingdom.
- Bobby Gaspar
Bobby Gaspar自2016年2月起担任我们的首席科学官和董事会成员。Gaspar博士加入UCL和Gosh，对基因治疗感兴趣。2007年10月以来，他一直担任UCL Institute of Child Health的儿科和免疫学教授，以及Gosh的儿科免疫学荣誉顾问。Gaspar博士拥有伦敦国王学院（Kings College London）的工商管理硕士学位和UCL的博士学位。
Bobby Gaspar has served as our Chief Scientific Officer and as a member of our board of directors since February 2016. Dr. Gaspar joined UCL and GOSH with an interest in gene therapy. Since October 2007 he has been professor of pediatrics and immunology at the UCL Institute of Child Health and Honorary Consultant in pediatric immunology at GOSH. Dr. Gaspar holds an M.B. B.S. from Kings College London and a Ph.D. from UCL.- Bobby Gaspar自2016年2月起担任我们的首席科学官和董事会成员。Gaspar博士加入UCL和Gosh，对基因治疗感兴趣。2007年10月以来，他一直担任UCL Institute of Child Health的儿科和免疫学教授，以及Gosh的儿科免疫学荣誉顾问。Gaspar博士拥有伦敦国王学院（Kings College London）的工商管理硕士学位和UCL的博士学位。
- Bobby Gaspar has served as our Chief Scientific Officer and as a member of our board of directors since February 2016. Dr. Gaspar joined UCL and GOSH with an interest in gene therapy. Since October 2007 he has been professor of pediatrics and immunology at the UCL Institute of Child Health and Honorary Consultant in pediatric immunology at GOSH. Dr. Gaspar holds an M.B. B.S. from Kings College London and a Ph.D. from UCL.
- Frank E. Thomas
Frank E. Thomas，在2011年8月加入Spero Therapeutics, Inc.，担任Spero Therapeutics, Inc.的执行副总裁、首席财务官和财务主管，目前担任执行副总裁兼首席运营官。从2011年11月至2012年5月，他还担任临时董事长和首席执行官。在加入Spero Therapeutics, Inc.之前，从2008年10月到2011年7月，他担任Molecular Biometrics商业阶段医疗诊断公司的高级副总裁、首席运营官和首席财务官。加入Molecular Biometrics之前，从2004年4月到2008年3月，他在Critical Therapeutics公共生物制药公司任职4年， 2006年6月，他被提升为总裁兼首席执行官，2006年12月，担任高级副总裁兼首席财务官。从2006年到2008年，他担任Critical Therapeutics的董事会主席。2004年之前，他担任Esperion Therapeutics生物制药公司的首席财务官和金融投资副董事长。自2007年起，他一直担任麻萨诸塞州生物技术委员会的董事会成员。他持有安娜堡密歇根大学的商业管理学士学位。
Frank E. Thomas,has served on Spero Therapeutics, Inc. Board of Directors since July 2017. Mr. Thomas is currently President and Chief Operating Officer of Orchard Therapeutics, a development-stage biotechnology company based in the United Kingdom, where he served as Chief Financial Officer and Chief Business Officer from January 2018 to March 2020. Prior to Orchard, Mr. Thomas served as the President and Chief Operating Officer of AMAG Pharmaceuticals, Inc., a commercial-stage pharmaceutical company, which was a publicly traded company that was subsequently acquired by Covis Pharma, from April 2015 to April 2017, as AMAG's Executive Vice President and Chief Operating Officer from May 2012 through April 2015 and as Executive Vice President, Chief Financial Officer and Treasurer from August 2011 through May 2012. Prior to AMAG, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., a commercial-stage medical diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., which was a publicly traded company that subsequently merged with Cornerstone Therapeutics Inc., from April 2004 to March 2008, where he was promoted to President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the board of directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr. Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a public biopharmaceutical company (Nasdaq: ESPR). Mr. Thomas was a member of the board of directors of the Massachusetts Biotechnology Council from 2007 to 2015. Mr. Thomas currently serves as a member of the board of directors of Larimar Therapeutics Inc (Nasdaq: LRMR). Mr. Thomas holds a B.B.A. from the University of Michigan, Ann Arbor.- Frank E. Thomas，在2011年8月加入Spero Therapeutics, Inc.，担任Spero Therapeutics, Inc.的执行副总裁、首席财务官和财务主管，目前担任执行副总裁兼首席运营官。从2011年11月至2012年5月，他还担任临时董事长和首席执行官。在加入Spero Therapeutics, Inc.之前，从2008年10月到2011年7月，他担任Molecular Biometrics商业阶段医疗诊断公司的高级副总裁、首席运营官和首席财务官。加入Molecular Biometrics之前，从2004年4月到2008年3月，他在Critical Therapeutics公共生物制药公司任职4年， 2006年6月，他被提升为总裁兼首席执行官，2006年12月，担任高级副总裁兼首席财务官。从2006年到2008年，他担任Critical Therapeutics的董事会主席。2004年之前，他担任Esperion Therapeutics生物制药公司的首席财务官和金融投资副董事长。自2007年起，他一直担任麻萨诸塞州生物技术委员会的董事会成员。他持有安娜堡密歇根大学的商业管理学士学位。
- Frank E. Thomas,has served on Spero Therapeutics, Inc. Board of Directors since July 2017. Mr. Thomas is currently President and Chief Operating Officer of Orchard Therapeutics, a development-stage biotechnology company based in the United Kingdom, where he served as Chief Financial Officer and Chief Business Officer from January 2018 to March 2020. Prior to Orchard, Mr. Thomas served as the President and Chief Operating Officer of AMAG Pharmaceuticals, Inc., a commercial-stage pharmaceutical company, which was a publicly traded company that was subsequently acquired by Covis Pharma, from April 2015 to April 2017, as AMAG's Executive Vice President and Chief Operating Officer from May 2012 through April 2015 and as Executive Vice President, Chief Financial Officer and Treasurer from August 2011 through May 2012. Prior to AMAG, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., a commercial-stage medical diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., which was a publicly traded company that subsequently merged with Cornerstone Therapeutics Inc., from April 2004 to March 2008, where he was promoted to President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the board of directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr. Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a public biopharmaceutical company (Nasdaq: ESPR). Mr. Thomas was a member of the board of directors of the Massachusetts Biotechnology Council from 2007 to 2015. Mr. Thomas currently serves as a member of the board of directors of Larimar Therapeutics Inc (Nasdaq: LRMR). Mr. Thomas holds a B.B.A. from the University of Michigan, Ann Arbor.